As of 2024-09-12, the EV/EBITDA ratio of Coherus BioSciences Inc (CHRS) is -1.82. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CHRS's latest enterprise value is 258.09 mil USD. CHRS's TTM EBITDA according to its financial statements is -142.05 mil USD. Dividing these 2 quantities gives us the above CHRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.9x - 10.5x | 8.9x |
| Forward P/E multiples | 7.0x - 15.7x | 10.3x |
| Fair Price | (10.68) - (13.88) | (12.75) |
| Upside | -902.6% - -1143.7% | -1058.4% |
| Date | EV/EBITDA |
| 2024-09-11 | -1.82 |
| 2024-09-10 | -1.84 |
| 2024-09-09 | -1.80 |
| 2024-09-06 | -1.74 |
| 2024-09-05 | -1.81 |
| 2024-09-04 | -1.80 |
| 2024-09-03 | -1.84 |
| 2024-08-30 | -1.87 |
| 2024-08-29 | -1.89 |
| 2024-08-28 | -1.84 |
| 2024-08-27 | -1.87 |
| 2024-08-26 | -1.91 |
| 2024-08-23 | -1.87 |
| 2024-08-22 | -1.81 |
| 2024-08-21 | -1.83 |
| 2024-08-20 | -1.75 |
| 2024-08-19 | -1.76 |
| 2024-08-16 | -1.76 |
| 2024-08-15 | -2.00 |
| 2024-08-14 | -1.85 |
| 2024-08-13 | -1.91 |
| 2024-08-12 | -1.92 |
| 2024-08-09 | -1.90 |
| 2024-08-08 | -1.78 |
| 2024-08-07 | -1.74 |
| 2024-08-06 | -1.82 |
| 2024-08-05 | -1.81 |
| 2024-08-02 | -1.83 |
| 2024-08-01 | -1.90 |
| 2024-07-31 | -1.99 |
| 2024-07-30 | -1.99 |
| 2024-07-29 | -2.07 |
| 2024-07-26 | -2.13 |
| 2024-07-25 | -2.02 |
| 2024-07-24 | -1.96 |
| 2024-07-23 | -2.08 |
| 2024-07-22 | -2.12 |
| 2024-07-19 | -2.07 |
| 2024-07-18 | -2.01 |
| 2024-07-17 | -2.15 |
| 2024-07-16 | -2.20 |
| 2024-07-15 | -2.08 |
| 2024-07-12 | -2.08 |
| 2024-07-11 | -2.04 |
| 2024-07-10 | -1.90 |
| 2024-07-09 | -1.91 |
| 2024-07-08 | -1.77 |
| 2024-07-05 | -1.82 |
| 2024-07-03 | -1.87 |
| 2024-07-02 | -1.87 |